We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Homologous recombination deficiency and glycolysis‐related pathway in adjuvant chemotherapy for triple‐negative breast cancer: A genomic landscape and biomarker assessment of the PATTERN trial.
- Authors
Zhu, Si‐Yuan; Ma, Ding; Ye, Fu‐Gui; Shao, Zhi‐Ming; Yu, Ke‐Da
- Abstract
(B) Patients in the PCb group and the CEF-T group were ordered by a representative pathway concerning hypoxia and glycolysis. Upregulation of glycolysis and hypoxia-related pathways was associated with inferior prognosis of patients treated by adjuvant anthracycline/taxane regimen. Abbreviations BCS breast conservative surgery BLIS basal-like and immune-suppressed CEF-T fluorouracil, epirubicin, and cyclophosphamide followed by docetaxel FUSCC Fudan University Shanghai Cancer Center HRD homologous recombination deficiency IM immunomodulatory IQR interquartile range LAR luminal androgen receptor MES mesenchymal-like PCb paclitaxel and carboplatin Triple-negative breast cancer (TNBC) is associated with genome-wide instability caused by mutations in homologous recombination repair mechanism,1 and the application of DNA-damaging compounds has been explored for TNBC.2 Recently, we performed the PATTERN trial (NCT01216111) to compare six cycles of paclitaxel plus carboplatin (PCb) with a standard-dose regimen of three cycles of cyclophosphamide/epirubicin/fluorouracil followed by three cycles of docetaxel (CEF-T) in the adjuvant setting of early-stage TNBC, and the result indicated a superior efficacy of the carboplatin-containing regimen and good tolerance to both treatments.3 In this study, we conducted multi-omic profiling on 132 patients in the PATTERN cohort to investigate potential biomarkers for a more precise choice of adjuvant chemotherapy regimen for TNBC.
- Subjects
TRIPLE-negative breast cancer; CANCER chemotherapy; LANDSCAPE assessment; PACLITAXEL; ADJUVANT chemotherapy; GLYCOLYSIS; GENETIC mutation; BREAST cancer
- Publication
Clinical & Translational Medicine, 2021, Vol 11, Issue 9, p1
- ISSN
2001-1326
- Publication type
Article
- DOI
10.1002/ctm2.513